News provider Globes said Aharon Schwartz, vice-president of Teva Innovative Ventures, would be "responsible for investing in start-ups and reaching licensing agreements with universities as part of the company's effort to expand its pipeline of innovative drugs".
Teva Pharmaceutical Industries, a Nasdaq and Israel-listed drugs maker, is reportedly planning to set up a corporate venturing fund having made several successful minority equity investments from its balance sheet historically.
News provider Globes said Aharon Schwartz (pictured), vice-president of Teva Innovative Ventures, would be "responsible for investing in start-ups and reaching licensing agreements with universities as part of the company’s effort to expand its pipeline of innovative drugs". Schwartz was unavailable on his email.
Teva’s exisitng early-stage investments…
